| 产品详情 |
| Edit |   |
|---|
| Product Name | dTAG-13 |
|---|
| Description | Thalidomide-based PROTAC targeting mutant FKBP12F36V fusion proteins. Comprises a ligand selective for F36V single-point mutated FKBP12, a linker and the cereblon-binding ligand, Thalidomide (Cat. No. 0652). FKBP12F36V can be expressed as a fusion with a target protein of interest using genome engineering techniques (via transgene expression or CRISPR-mediated locus-specific knock-in). Application of dTAG-13 induces rapid, reversible and selective degradation of FKBP12F36V fusion proteins in vitro and in vivo. dTAG is generalizable to a range of fusion proteins; useful as an alternative to genetic methods for target validation. Plasmid vectors for the lentiviral expression and CRISPR-mediated knock-in of FKBP12F36V are available from Addgene.. Purity 98%. MW (observed): 1049.18 |
|---|
| Size | 5 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 1-[(2S)-1-Oxo-2-(3,4,5-trimethoxyphenyl)butyl]-(2S)-2-piperidinecarboxylate (1R)-3-(3,4-dimethoxyphenyl)-1-[2-[2-[[6-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]hexyl]amino]-2-oxoethoxy]phenyl]propyl ester |
|---|
| Gene, Accession, CAS # | CAS: 2064175-41-1 |
|---|
| Catalog # | 6605/5 |
|---|
| Price | |
|---|
| Order / More Info | dTAG-13 from TOCRIS BIOSCIENCE
|
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|